Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study
Most Cited Paper
in Monoclonal and Polyclonal Antibodies Research
18 Months Post-Publication
Class of 2026
“Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/monoclonal-and-polyclonal-antibodies-research/2026/
Topics
Mosunetuzumab · CD20-targeted therapy · T-cell-engaging bispecific antibody · relapsed/refractory indolent B-cell non-Hodgkin lymphoma · relapsed/refractory aggressive B-cell non-Hodgkin lymphoma · Fixed-duration treatment · Off-the-shelf therapy · Outpatient administration · Phase I/II trial · Duration of response · Complete response rate · retreatment upon progression · durable remission · NCT02500407 · extended follow-up analysis · Objective response rate
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Monoclonal and Polyclonal Antibodies Research Papers, Class of 2026. https://pri.pepkio.com/top-papers/monoclonal-and-polyclonal-antibodies-research/2026. Accessed 2026-07-15. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459